A partnership for improving 340B discount validations: Collaboration fueled a data-driven approach to disputes

Many drug manufacturers come up against the systemic challenge of noncompliant drug discounts that cause revenue leakage and adversely impact business operations. 

When state Medicaid agencies advised Company V to work directly with covered entities to resolve disputes related to noncompliance, the manufacturer faced a complex challenge: It did not have the time and resources necessary to engage with the appropriate parties on 340B validations.

Company V approached Kalderos for support. With a multi-sided platform solution, Kalderos could help the manufacturer accomplish its goals in collaboration with our extensive network of covered entities.

Read more about how Kalderos and Company V worked together to dispute several millions of dollars in noncompliance.